Prothena Corp Public (PRTA) Short-term Investments (2019 - 2024)
Prothena Corp Public (PRTA) posted quarterly Short-term Investments of $1.4 million for Q1 2024, little changed quarter-over-quarter from $1.4 million in Q4 2023.
Analysis
Prothena Corp Public (PRTA) Short-term Investments (2019 - 2024) Analysis & Trends
Prothena Corp Public's Short-term Investments history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2024.
- In Q1 2024, Short-term Investments changed N/A year-over-year to $1.4 million; the TTM figure through Mar 2024 stood at $1.4 million (changed N/A YoY), while the FY2023 annual figure was $1.4 million, changed N/A from the prior year.
- Short-term Investments for Q1 2024 stood at $1.4 million, roughly flat from $1.4 million in the prior quarter.
- The five-year high for Short-term Investments was $1.4 million in Q3 2020, with the low at $1.4 million in Q3 2020.
- The 4-year median for Short-term Investments is $1.4 million (2020), against an average of $1.4 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 513.11 Mn | 224.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Jun 30, 2021 | 1.35 Mn |
| Mar 31, 2021 | 1.35 Mn |
| Dec 31, 2020 | 1.35 Mn |
| Sep 30, 2020 | 1.35 Mn |
| Jun 30, 2019 | 1.35 Mn |
| Mar 31, 2019 | 1.35 Mn |